The short answer
Veozah is an FDA-approved, nonhormonal prescription for moderate-to-severe vasomotor symptoms due to menopause. It blocks the neurokinin 3 receptor rather than supplying estrogen. Its current U.S. label carries a boxed warning for hepatotoxicity and requires liver testing before treatment, monthly for the first three months, and again at months 6 and 9.
Boxed warning: risk of hepatotoxicity
Serious liver injury has occurred after marketing. The FDA label requires hepatic laboratory tests before starting; treatment should not begin if either aminotransferase is at least twice the upper limit of normal or total bilirubin is at least twice the upper limit of normal.
Testing is required monthly for the first 3 months, then at months 6 and 9. Stop the medication and seek medical guidance immediately for new fatigue, reduced appetite, nausea, vomiting, itching, yellow skin or eyes, pale stool, dark urine, or abdominal pain.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Veozah (fezolinetant) tablets | 2026-02-26 | Hepatotoxicity |
Established evidence
What Veozah is approved to treat
The FDA indication is moderate-to-severe vasomotor symptoms due to menopause. Vasomotor symptoms include hot flashes and night sweats. The approval does not make Veozah a general treatment for every menopause symptom.
Established evidence
How fezolinetant works without estrogen
Falling estrogen changes signaling in hypothalamic KNDy neurons involved in temperature regulation. Fezolinetant blocks neurokinin B signaling at the NK3 receptor, helping stabilize the thermoregulatory pathway. It does not contain estrogen and is not hormone therapy.
Established evidence
What the clinical trials established
Randomized phase 3 trials found reductions in the frequency and severity of moderate-to-severe vasomotor symptoms compared with placebo. Trial averages cannot predict an individual response, and there is no basis to promise a specific percentage of relief.
Established evidence
How quickly did Veozah work in trials?
The FDA review evaluated symptom changes at weeks 4 and 12, with participants followed longer for safety. Group-level improvements can begin before those checkpoints, but the label does not guarantee that a particular person will improve within a fixed number of days. A prescriber should reassess persistent symptoms and whether continued treatment remains appropriate.
Established evidence
Contraindications and interactions
- Known cirrhosis
- Severe renal impairment or end-stage renal disease
- Use with CYP1A2 inhibitors
- Any situation in which required liver monitoring cannot be completed
Established evidence
Veozah side effects: common reactions and urgent warning signs
The label lists abdominal pain, diarrhea, insomnia, back pain, hot flush, and elevated hepatic transaminases among the most common adverse reactions. These trial findings are different from the rare but serious postmarketing liver injury described in the boxed warning.
New fatigue, reduced appetite, nausea, vomiting, itching, jaundice, pale stool, dark urine, or abdominal pain require immediate medication discontinuation and medical evaluation under the current label. A licensed professional should also review other medicines, kidney and liver history, and unexplained symptoms.
Established evidence
Veozah liver-test schedule
Before treatment, the label calls for alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and total and direct bilirubin testing. Follow-up hepatic laboratory tests are required monthly during months 1, 2, and 3, then at months 6 and 9.
The prescribing information contains specific stopping rules when liver tests rise or symptoms occur. This schedule is not optional routine wellness testing; it is part of the labeled safety framework for the medicine.
Veozah cost, insurance, and coupon searches
The amount a patient pays can vary by insurance benefit design, deductible, pharmacy, location, and any manufacturer eligibility rules. Kindr Health does not publish an unverified cash price or promise coupon eligibility. For a current estimate, patients can ask their insurer and dispensing pharmacy to check the exact prescription and benefit at the time it is written.
How to interpret Veozah reviews
Patient reviews can describe lived experience, but they cannot establish average effectiveness, detect uncommon harms, or show whether another person has the same risk factors. Randomized trials, the FDA label, postmarketing safety updates, and an individual clinical assessment provide a stronger basis for decisions than testimonials alone.
How it fits among hot-flash options
Veozah is one nonhormonal option. Hormone therapy, certain antidepressants, gabapentin, oxybutynin, and behavioral approaches have different evidence, risks, and trade-offs. Choice depends on symptom burden, medical history, preferences, interactions, and access to follow-up—not on a universal ranking.
Questions, answered
What people ask about Veozah
Is Veozah a hormone?+
No. Fezolinetant is a neurokinin 3 receptor antagonist and does not supply estrogen.
What liver tests are required with Veozah?+
The current FDA label requires liver tests before starting, monthly for the first 3 months, and again at months 6 and 9.
Does Veozah have a boxed warning?+
Yes. The current U.S. label has a boxed warning for hepatotoxicity after serious liver injury occurred in the postmarketing setting.
Can Veozah be used with CYP1A2 inhibitors?+
No. Concomitant use with CYP1A2 inhibitors is contraindicated under the FDA label.
How much does Veozah cost?+
There is no single reliable price. Out-of-pocket cost varies with insurance, deductible, pharmacy, location, and current manufacturer-program eligibility. Verify the exact prescription with the insurer and pharmacy.
How quickly does Veozah work?+
Clinical trials assessed key symptom outcomes at weeks 4 and 12, but an individual response may differ. The evidence does not support promising relief within a specific number of days.
Does Kindr Health offer Veozah?+
This page does not state or imply that Veozah is available through Kindr Health. It is an educational resource.
Kindr Health does not claim to offer Veozah on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn about Kindr Health care pathways. This is separate from any claim that Veozah is available.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- VEOZAH (fezolinetant) prescribing information (2024) — U.S. Food and Drug Administration. www.accessdata.fda.gov/drugsatfda_docs/label/2024/216578s004lbl.pdf
- FDA adds warning about rare occurrence of serious liver injury with Veozah (2024) — U.S. Food and Drug Administration. www.fda.gov/safety/medical-product-safety-information/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due
- Drug Trials Snapshot: VEOZAH (2023) — U.S. Food and Drug Administration. www.fda.gov/drugs/drug-trials-snapshots/drug-trials-snapshots-veozah
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.